EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

BACKGROUND: EGFR‐tyrosine kinase inhibitors play an important role in the treatment of advanced non‐small cell lung cancer (NSCLC). EGFR mutations in advanced NSCLC occur in approximately 35% of Asian patients and 60% of patients with adenocarcinoma. However, the frequency and type of EGFR mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Pi, Can, Xu, Chong‐Rui, Zhang, Ming‐feng, Peng, Xiao‐xiao, Wei, Xue‐wu, Gao, Xing, Yan, Hong‐Hong, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026603/
https://www.ncbi.nlm.nih.gov/pubmed/29722148
http://dx.doi.org/10.1111/1759-7714.12651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026603/
https://www.ncbi.nlm.nih.gov/pubmed/29722148
http://dx.doi.org/10.1111/1759-7714.12651

Ejemplares similares